{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.3","upperLimit":"39.9","value":"36.5"},{"groupId":"OG001","lowerLimit":"32.7","upperLimit":"39.3","value":"35.9"}]}],"title":"At Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.7","upperLimit":"46.8","value":"43.2"},{"groupId":"OG001","lowerLimit":"40.2","upperLimit":"47.3","value":"43.7"}]}],"title":"At Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.6","upperLimit":"54.6","value":"50.6"},{"groupId":"OG001","lowerLimit":"46.6","upperLimit":"54.5","value":"50.5"}]}],"title":"At Week 109"}],"denoms":[{"counts":[{"groupId":"OG000","value":"859"},{"groupId":"OG001","value":"859"}],"units":"Participants"}],"description":"A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to receive zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaneously once every 4 weeks in the double-blind treatment phase.","id":"OG000","title":"Zoledronic Acid"},{"description":"Participants randomized to receive denosumab 120 mg subcutaneously plus placebo to zoledronic acid intravenously once every 4 weeks in the double-blind treatment phase.","id":"OG001","title":"Denosumab"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively. The Kaplan-Meier estimate at weeks 25, 49 and 109 is reported.","title":"Kaplan-Meier Estimate of Percentage of Participants With an On-study Skeletal Related Event","type":"PRIMARY","unitOfMeasure":"percentage of participants"}